The significance of immune-related molecule expression profiles in an animal model of Graves' disease

Autoimmunity

Volumn 45, Issue 2, 2012, Pages 143-152

  Ye, Feng ^a,b   Hou, Peng ^a   Wu, Xiaoyan ^a   Ma, Xiaodan ^a   Gao, Lei ^a   Wu, Liping ^a   Xu, Li ^a   Shi, Bingyin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Animal model; Co stimulatory molecules; FOXP3; Graves' disease; IL 17

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 17; PHOSPHATE BUFFERED SALINE; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN RECEPTOR; THYROXINE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GRAVES DISEASE; HEART; IMMUNOPATHOLOGY; LIVER; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; THYROID FUNCTION; THYROID GLAND; THYROXINE BLOOD LEVEL;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD40; ANTIGENS, CD86; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENETIC VECTORS; GRAVES DISEASE; HUMANS; MICE; MICE, INBRED BALB C; RECEPTORS, THYROTROPIN; THYROID GLAND; THYROXINE;

EID: 84863063188     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.611548     Document Type: Article

References (46)

1. Mizutori Y, Chen CR, Latrofa F, McLachlan SM, Rapoport B. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease. J Clin Endocr Metab 2009;94:927-935.
2. Ludgate M. Animal models of Graves' disease. Eur J Endocrinol 2000;142:1-8. (Pubitemid 30094192)
3. Pichurin PN, Chen CR, Chazenbalk GD, Aliesky H, Pham N, Rapoport B, McLachlan SM. Targeted expression of the human thyrotropin receptor A-subunit to the mouse thyroid: Insight into overcoming the lack of response to A-subunit adenovirus immunization. J Immunol 2006;176:668-676. (Pubitemid 43023316)
4. Chazenbalk GD, Pichurin P, Chen C-R, Latrofa F, Johnstone AP, McLachlan SM, Rapoport B. Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. J Clin Invest 2002;110:209-217. (Pubitemid 34787358)
5. Chazenbalk GD, Chen C-R, McLachlan SM, Rapoport B. Does thyrotropin cleave its cognate receptor? Endocrinology 2004 145 4-10. (Pubitemid 38094492)
6. Isaacs JD. Therapeutic T-cell manipulation in rheumatoid arthritis: Past, present and future. Rheumatology 2008;47: 1461-1468.
7. McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves' hyperthyroidism from animal models. Endocr Rev 2005;26:800-832. (Pubitemid 41428539)
8. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003;24:802-835. (Pubitemid 38067700)
9. Brunner-Weinzierl MC, Hoff H, Burmester G-R. Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: Implications for arthritis and autoimmune diseases. Arthritis Res Ther 2004;6: 45-54. (Pubitemid 38444461)
10. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3 regulatory T cell function. Science 2008;322: 271-275.
11. Marks BR, Nowyhed HN, Choi JY, Poholek AC, Odegard JM, Flavell RA, Craft J. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat Immunol 2009;10:1125-1132.
12. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: The Th17 lineage. Curr Opin Immunol 2006;18:349-356.
13. Nagayama Y, Kita-Furuyama M, Ando T, Nakao K, Mizuguchi H, Hayakawa T, Eguchi K, Niwa M. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 2002;168:2789-2794. (Pubitemid 34211657)
14. Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest 2003;111:1897-1904. (Pubitemid 38057734)
15. Shah R, Banks K, Patel A, Dogra S, Terrell R, Powers PA, Fenton C, Dinauer CA, Tuttle RM, Francis GL. Intense expression of the B7-2 antigen presentation coactivator is an unfavorable prognostic indicator for differentiated thyroid carcinoma of children and adolescents. J Clin Endocr Metab 2002;87:4391-4397.
16. Suzuki M, Zheng XF, Zhang XS, Li M, Vladau C, Ichim TE, Sun HT, Min SR, Garcia B, Min WP. Novel vaccination for allergy through gene silencing of CD40 using small interfering RNA. J Immunol 2008;180:8461-8469.
17. Chen C-R, Aliesky H, Pichurin PN, Nagayama Y, McLachlan SM, Rapoport B. Susceptibility rather than resistance to hyperthyroidism is dominant in a thyrotropin receptor adenovirus-induced animal model of Graves' disease as revealed by BALB/c-C57BL/6 hybrid mice. Endocrinology 2004;145:4927-4933. (Pubitemid 39551109)
18. Land KJ, Gudapati P, Kaplan MH, Seetharamaiah GS. Differential requirement of signal transducer and activator of transcription-4 (Stat4) and Stat6 in a thyrotropin receptor- 289-adenovirus-induced model of Graves' hyperthyroidism. Endocrinology 2006;147:111-119. (Pubitemid 43004266)
19. Mizutori Y, Saitoh O, Eguchi K, Nagayama Y. Adenovirus encoding the thyrotropin receptor A-subunit improves the efficacy of dendritic cell-induced Graves' hyperthyroidism in mice. J Autoimmun 2006;26:32-36. (Pubitemid 43138890)
20. Bhatia S, Edidin M, Almo SC, Nathenson SG. B7-1 and B7-2: Similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol Lett 2006; 104:70-75. (Pubitemid 43330711)
21. Inukai Y, Momobayashi A, Sugawara N, Aso Y. Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein- 10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. Eur J Endocrinol 2007;156:623-630. (Pubitemid 46952531)
22. Kallmann BA, Huther M, Tubes M, Feldkamp J, Bertrams J, Gries FA, Lampeter EF, Kolb H. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes 1997;46:237-243. (Pubitemid 27272257)
23. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol 2003;170:3522-3527. (Pubitemid 36359218)
24. Saitoh O, Mizutori Y, Takamura N, Yamasaki H, Kita A, Kuwahara H, Nagayama Y. Adenovirus-mediated gene delivery of interleukin-10, but not transforming growth factor beta, ameliorates the induction of Graves' hyperthyroidism in BALB/c mice. Clin Exp Immunol 2005;141:405-411. (Pubitemid 41075863)
25. Nagayama Y, Saitoh O, McLachlan SM, Rapoport B, Kano H, Kumazawa Y. TSH receptor-adenovirus-induced Graves' hyperthyroidism is attenuated in both interferon-gamma and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm. Clin Exp Immunol 2004;138:417-422. (Pubitemid 39573620)
26. Ye F, Shi BY, Wu XY, Hou P, Gao L, Ma XD, Xu L, Wu LP. Experience with lentivirus-mediated CD40 gene silencing in a mouse model of Graves' disease. J Endocrinol 2011;208: 285-291.
27. Faure GC, Bensoussan-Lejzerowicz D, Bene MC, Aubert V, Leclere J. Coexpression of CD40 and class II antigen HLADR in Graves' disease thyroid epithelial cells. Clin Immunol Immunopathol 1997;84:212-215. (Pubitemid 27353475)
28. Kie JH, Cho MS, Yang WI. Expression of CD40 and apoptosis related molecules in autoimmune thyroid diseases. Yonsei Med J 2001;42:488-496.
29. Metcalfe RA, McIntosh RS, Marelli-Berg F, Lombardi G, Lechler R, Weetman AP. Detection of CD40 on human thyroid follicular cells: Analysis of expression and function. J Clin Endocrinol Metab 1998;83:1268-1274. (Pubitemid 28496407)
30. Smith TJ, Sciaky D, Phipps RP, Jennings TA. CD40 expression in human thyroid tissue: Evidence for involvement of multiple cell types in autoimmune and neoplastic diseases. Thyroid 1999;9:749-755.
31. Tomer Y, Huber A. The etiology of autoimmune thyroid disease: A story of genes and environment. J Autoimmun 2009;32:231-239.
32. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995;96: 987-993.
33. Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996;5:285-293. (Pubitemid 26341371)
34. Nishikawa K, Linsley PS, Collins AB, Stamenkovic I, McCluskey RT, Andres G. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur J Immunol 1994;24:1249-1254. (Pubitemid 24169503)
35. Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, Spengler U. Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol 1999;154: 1711-1720. (Pubitemid 29262853)
36. Stumpf C, Lehner C, Eskafi S, Raaz D, Yilmaz A, Ropers S, Schmeisser A, Ludwig J, Daniel WG, Garlichs CD. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003;5:629-637. (Pubitemid 38043968)
37. Yan J-C, Liu P-J, Du R-Z, Liang Y, Ma G-S, Zhu J, Luo D. Relationship between CD40 ligand expression and B type natriuretic peptide levels in patients with chronic heart failure. Clin Chim Acta 2008;392:17-20.
38. Santilli F, Basili S, Ferroni P, Davi G. CD40/CD40L system and vascular disease. Intern Emerg Med 2007;2:256-268.
39. Ueland T, Aukrust P, Yndestad A, Otterdal K, Froland SS, Dickstein K, Kjekshus J, Gullestad L, Damas JK. Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 2005;26:1101-1107. (Pubitemid 40839911)
40. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594. (Pubitemid 28157601)
41. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995;92:4342-4346.
42. Watanabe K, Iwatani Y, Hidaka Y, Watanabe M, Amino N. Long-term effects of thyroid hormone on lymphocyte subsets in spleens and thymuses of mice. Endocr J 1995;42:661-668.
43. Ziegler SF, Buckner JH. FOXP3 and the regulation of Treg/ Th17 differentiation. Microbes Infect 2009;11:594-598.
44. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238.
45. Zhou L, Lopes JE, Chong MMW, Ivanov II, Min R, Victora GD, Shen Y, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453:236-240. (Pubitemid 351667978)
46. Dutzan N, Gamonal J, Silva A, Sanz M, Vernal R. Overexpression of forkhead box P3 and its association with receptor activator of nuclear factor-kappa B ligand, interleukin (IL) -17, IL-10 and transforming growth factor-beta during the progression of chronic periodontitis. J Clin Periodontol 2009;36:396-403.